Trombovazim (Trombovazime / Trombovazim)

✓ Approved

Segmenta Pharmaceuticals · therapeutic agent

What is Trombovazim?

Trombovazim is a therapeutic agent developed by Segmenta Pharmaceuticals. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Names	Trombovazime, Trombovazim
Company	Segmenta Pharmaceuticals
Route	Oral (PO)
Status	Approved

Sources: ClinicalTrials.gov, Segmenta Pharmaceuticals

Therapeutic Indications

Trombovazim is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic Area	Condition	Phase
Vascular disorders	Peripheral venous disease	✓ Approved
Cardiac disorders	Myocardial infarction	Preclinical

Related Research Articles

PubMedBulletin of experimental biology and medicine2012-07-19

Evaluation of anti-inflammatory effects of Trombovazim in the model of liver ischemia-reperfusion.

Churin A A AA, Ermolaeva L A LA, Dubskaya T Yu TY, Fomina T I TI et al.

Administration of enzyme preparation Trombovazim as a corrector of ischemic damage to animals with experimental liver ischemia-reperfusion reduces neutrophilic infiltration of liver parenchyma and decreases hyperfermentemia, which attests to a decrease in the intensity of destructive changes in hepatocytes.

PMID 22808462

Read full article →

PubMedBulletin of experimental biology and medicine2009-08-26

Antithrombotic and thrombolytic effects of a new proteolytic preparation Trombovazim (Russia).

Plotnikov M B MB, Dygai A M AM, Aliev O I OI, Chernyshova G A GA et al.

We studied the antithrombotic and thrombolytic effects of Trombovazim, a highly-purified proteolytic enzyme preparation obtained by immobilization of bacterial proteinases (Bacillus) on polyethylene oxide with a molecular weight of 1.5 kDa. Blood absorption of the preparation was evaluated after intragastric administration. In vitro experiments showed that Trombovazim produces anticoagulant and thrombolytic effects, which manifested in inhibition of fibrin clot formation and acceleration of its lysis. Drug concentration in the blood was elevated from the 4th to the 7th hour after intragastric administration of Trombovazim in a dose of 2250 U/kg, being maximum by the 5th hour (0.044+/-0.011 U/ml). Course treatment with Trombovazim (1000 U intragastrically, twice daily for 3 days) had a thrombolytic effect on rats with experimental intravascular thrombosis. This effect was manifested in a decrease in thrombus weight and increase in the percent of rats with recanalization of the occluded carotid artery.

PMID 19704943